Using subjective cognitive decline to identify high global amyloid in community‐based samples: A cross‐cohort study
Abstract
We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β‐amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2019
- Source ID
- 10.1016/j.dadm.2019.08.004
Entities
People
- Aaron P. Schultz
- Colin L. Masters
- Dorene M. Rentz
- Elizabeth C. Mormino
- Jennifer S. Rabin
- Kathryn V. Papp
- Keith A. Johnson
- Michael J. Properzi
- Rachel F Buckley
- Rebecca E. Amariglio
- Reisa A. Sperling
- Samantha Burnham
- Sietske Sikkes
- Victor L. Villemagne
- Vincent Doré
Organizations
- AbbVie
- Alzheimer's Disease Neuroimaging Initiative
- Biogen
- Canadian Institutes of Health Research
- Centre d'Imagerie BioMedicale
- Commonwealth Scientific and Industrial Research Organisation
- Eisai
- Eli Lilly and Company
- Fidelity Biosciences (United States)
- Harvard Medical School
- Harvard NeuroDiscovery Center
- Janssen Pharmaceuticals
- Massachusetts General Hospital
- National Health and Medical Research Council
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Stanford University
- United States Department of Defense
- University of Melbourne
- Vrije Universiteit Amsterdam